These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Bell DA; Hooper AJ; Watts GF; Burnett JR Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Gelsinger C; Steinhagen-Thiessen E; Kassner U Drugs; 2012 Jul; 72(11):1445-55. PubMed ID: 22799743 [TBL] [Abstract][Full Text] [Related]
9. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758 [TBL] [Abstract][Full Text] [Related]
10. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Bell DA; Hooper AJ; Burnett JR Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice. Marbach JA; Thapa J; Goldenberg E; Duffy D Del Med J; 2015 Aug; 87(8):238-43. PubMed ID: 26402926 [TBL] [Abstract][Full Text] [Related]
12. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia. Won JI; Zhang J; Tecson KM; McCullough PA Rev Cardiovasc Med; 2017; 18(1):21-28. PubMed ID: 28509890 [TBL] [Abstract][Full Text] [Related]
13. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. Robinson JG J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430 [TBL] [Abstract][Full Text] [Related]
14. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease. Vogt A; Parhofer KG Expert Opin Pharmacother; 2013 Apr; 14(6):691-7. PubMed ID: 23477485 [TBL] [Abstract][Full Text] [Related]
15. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. Vishwanath R; Hemphill LC J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684 [TBL] [Abstract][Full Text] [Related]
16. Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials. Li N; Li Q; Tian XQ; Qian HY; Yang YJ Am J Cardiovasc Drugs; 2014 Oct; 14(5):367-76. PubMed ID: 25027352 [TBL] [Abstract][Full Text] [Related]
17. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Rader DJ; Kastelein JJ Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695 [No Abstract] [Full Text] [Related]
18. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. Gouni-Berthold I; Berthold HK Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Reeskamp LF; Kastelein JJP; Moriarty PM; Duell PB; Catapano AL; Santos RD; Ballantyne CM Atherosclerosis; 2019 Jan; 280():109-117. PubMed ID: 30500603 [TBL] [Abstract][Full Text] [Related]